← All trials
NCT01847274
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 1, 2013
- Primary completion
- Jun 1, 2016
- Completion date
- Jun 1, 2016
- First posted
- —
- Last posted
- —
- Enrollment
- 597
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- TesaroLead sponsor
- Myrexis Inc.Collaborator
- University of CopenhagenOverall official - principal investigator
- Harvard UniversityOverall official - principal investigator
- Facing Our Risk of Cancer EmpoweredCollaborator
- SCRI Development InnovationsCollaborator
- Cooperative Ovarian Cancer Group for Immunotherapy NetworkCollaborator
- European Network for Gynaecological Oncological TrialCollaborator
- US OncologyCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.